I’m so hyped for this drug. This is my karxt

Medications
1
  • Evenamide Clinical Trials:
    • Study 014/015: Positive final one-year results from a Phase II open-label trial evaluating evenamide as an add-on therapy for treatment-resistant schizophrenia (TRS).
      • Significant, sustained improvement in Positive and Negative Syndrome Scale (PANSS) Total, Clinical Global Impression of Severity (CGI-S), and Level of Functioning (LOF).
      • Over 70% of patients experienced a clinically important reduction in disease severity.
      • 25% of patients achieved “remission,” a first for TRS patients.
    • Study 008A: Compelling results from a four-week randomized, double-blind, placebo-controlled study of evenamide as an add-on therapy for chronic schizophrenia.
      • Statistically significant multi-domain benefits in PANSS and Clinical Global Impression of Change (CGI-C) ratings.
      • Benefits increased over time, suggesting larger and enduring effects during long-term treatment.
  • Corporate Developments:
    • Newron is working towards initiating a potentially pivotal, multinational, randomized, double-blind, one-year, placebo-controlled study to assess evenamide’s efficacy, safety, and tolerability in TRS patients.
    • The company is in the process of securing a value-creating transaction around evenamide, with several indications of interest received.
    • An agreement was made for the subscription of up to 2.05 million newly issued shares, valued at up to EUR 15 million, with an institutional investor focused on high-growth biotech and healthcare firms.

These updates highlight Newron’s progress in developing innovative treatments for schizophrenia and their strategic efforts to enhance shareholder value12.

4 Likes
2

Being that it is an ‘add on’ medication, it means that the disabling effects of the original medications will still be doing their worst.

Surely, it would be better to have a med that does less damage in the first place?

3

If it doesn’t affect d2 receptors, then how can Doctors claim that d2 hyperactivity is the cause for positive symptoms of sz?

4

I am favoring this medication over KarXT as well.

The reason is that, Abilify wipes out the voices, but some symptoms remain for which I need a second antipsychotic. Abilify has no side effects for me, apart for a few pounds which are manageable with exercise. So, this would be a pretty safe combination, Abilify with Evanamide.

I have tried 20 APs none work like Abilify. What is the chance that one KArxt would wipe the symptoms out like Abilify? Maybe 15-20 percent, which is not much.

So, I am looking forward to Evenamide, as well.

The only thing is that if something you know that might help me with cognitive symptoms, it would be a blessing. So, if KARxt comes out, and it alleviates the cognitives, then I may want to try it in combination with Abilify. If Evenamide can address some of the cognitive issues, even better.

2 Likes
5

My situation is similar to @angledangle. Other than weight the side effects aren’t that bad for me. They certainly aren’t worse than the symptoms of the disease. When I initially got sick I was completely bed ridden. Totally deluded, couldn’t think straight, very very sick. For me meds improved my negatives.

1 Like